BeStock  
Stocks › Biotechnology › TSHA

Taysha Gene Therapies TSHA

US equityMarket cap rank #3032Biotechnology
$3.72 −$0.05 (-1.33%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.71 -0.27%
Open$3.67
Prev close$3.77
Day range$3.60 – $3.80
Volume3.15M
Market cap$1.21B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00-100.0% YoY
Operating profit-$50.78M-89.8% YoY
Net profit-$46.64M-73.5% YoY
Diluted EPS-$0.13-44.4% YoY
Free cash flow-$40.42M-100.3% YoY
Operating cash flow-$40.43M

Revenue, last 8 quarters

$1.8MSep '24$2.0MDec '24$2.3MMar '25$2.0MJun '25$0.0Sep '25$5.5MDec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-25.5MSep '24$-18.8MDec '24$-21.5MMar '25$-26.9MJun '25$-32.7MSep '25$-27.9MDec '25$-42.4MMar '26$-46.6MJun '26

Diluted EPS by quarter

-0.10Sep '24-0.07Dec '24-0.08Mar '25-0.09Jun '25-0.09Sep '25-0.08Dec '25-0.12Mar '26-0.13Jun '26

Free cash flow by quarter

$-21.7MSep '24$-18.3MDec '24$-22.4MMar '25$-20.2MJun '25$-24.3MSep '25$-27.0MDec '25$-43.9MMar '26$-40.4MJun '26

Annual revenue

$0.0FY20$0.0FY21$2.5MFY22$15.5MFY23$8.3MFY24$9.8MFY25

Profitability & balance sheet

Operating margin-2,854.9%
Net margin-2,728.0%
Return on equity-47.1%
Return on assets-37.2%
Return on invested capital-42.7%
Current ratio17.76
Liabilities / assets17.7%
Cash & investments$455.41M
Total debt$55.55M
Net cash (debt)$399.86M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $0.00 $0.00 – – $0.00
Total Operating Revenue $0.00 $0.00 $9.77M $5.49M $0.00
Operating Expense $50.78M $43.49M $120.27M $33.79M $34.02M
Selling and Admin Expenses $12.15M $9.68M $33.87M $8.83M $8.28M
-General & Admin Expense $12.15M $9.68M $33.87M $8.83M $8.28M
Research & Development $38.64M $33.81M $86.40M $24.95M $25.75M
Operating Profit -$50.78M -$43.49M -$110.50M -$28.30M -$34.02M
Net Non-Operating Interest Income (Expense) $2.32M $2.58M $9.16M $2.86M $3.15M
Non-Operating Interest Income $2.33M $2.59M $9.22M $2.87M $3.17M
Non-Operating Interest Expense $6,000.00 $9,000.00 $63,000.00 $12,000.00 $15,000.00
Other Income (Expense) $1.82M -$1.50M -$7.66M -$2.41M -$1.86M
Special Income (Charges) $3.43M – $0.00 $0.00 $0.00
-Less:Other Special Charges -$3.43M – – – –
Other Non-Operating Income (Expenses) -$1.61M -$1.50M -$6.46M -$1.67M -$1.57M
Pretax Profit -$46.64M -$42.41M -$109.00M -$27.85M -$32.73M
Net Profit -$46.64M -$42.41M -$109.00M -$27.85M -$32.73M
Profit from Continuing Operations -$46.64M -$42.41M -$109.00M -$27.85M -$32.73M
Net Income to Parent Company -$46.64M -$42.41M -$109.00M -$27.85M -$32.73M
Net Income to Common Stockholders -$46.64M -$42.41M -$109.00M -$27.85M -$32.73M
Basic EPS -$0.13 -$0.12 -$0.34 -$0.08 -$0.09
Diluted EPS -$0.13 -$0.12 -$0.34 -$0.08 -$0.09
Gain on Sale of Security – – -$1.20M -$736,000.00 -$292,000.00
-Less:Impairment of Capital Assets – – $0.00 $0.00 $0.00

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $470.43M $300.35M $343.32M $343.32M $316.55M
Total Current Assets $461.43M $282.25M $324.65M $324.65M $299.95M
Cash and Cash Equivalents & Short-Term Investments $455.41M $276.58M $319.77M $319.77M $297.34M
-Cash and Cash Equivalents $455.41M $276.58M $319.77M $319.77M $297.34M
Prepaid Assets $5.07M $4.02M $3.43M $3.43M $1.65M
Restricted Cash $0.00 $449,000.00 $449,000.00 $449,000.00 $449,000.00
Current Deferred Assets $110,000.00 $195,000.00 $195,000.00 $195,000.00 $57,000.00
Other Current Assets $851,000.00 $1.01M $802,000.00 $802,000.00 $456,000.00
Total Non-Current Assets $9.00M $18.10M $18.67M $18.67M $16.60M
Net PPE $8.73M $15.61M $16.18M $16.18M $14.27M
-Gross PPE $13.98M $20.58M $20.86M $20.86M $18.65M
-Accumulated Depreciation -$5.25M -$4.97M -$4.68M -$4.68M -$4.39M
Other Non-Current Assets $270,000.00 $2.50M $2.50M $2.50M $2.34M
Total Liabilities $83.17M $88.41M $96.38M $96.38M $97.57M
Total Current Liabilities $25.98M $20.10M $26.55M $26.55M $28.63M
Payables $9.16M $4.56M $6.28M $6.28M $5.44M
-Accounts Payable $9.16M $4.56M $6.28M $6.28M $5.44M
Current Accrued Expenses $9.92M $9.94M $8.21M $8.21M $9.04M
Short-Term Debt and Capital Lease Obligation $1.16M $1.82M $1.87M $1.87M $1.67M
-Current Capital Lease Obligation $1.16M $1.82M $1.87M $1.87M $1.67M
Other Current Liabilities $355,000.00 $784,000.00 $777,000.00 $777,000.00 $1.65M
Total Non-Current Liabilities $57.19M $68.31M $69.83M $69.83M $68.93M
Long Term Debt and Capital Lease Obligation $55.55M $66.73M $68.28M $68.28M $67.36M
-Long Term Debt $49.26M $48.96M $50.11M $50.11M $50.85M
-Long Term Capital Lease Obligation $6.29M $17.77M $18.17M $18.17M $16.51M
Other Non-Current Liabilities $1.64M $1.58M $1.55M $1.55M $1.58M
Total Equity $387.27M $211.94M $246.94M $246.94M $218.99M
Stockholders' Equity $387.27M $211.94M $246.94M $246.94M $218.99M
Capital Stock $3,000.00 $3,000.00 $3,000.00 $3,000.00 $3,000.00
-Common Stock $3,000.00 $3,000.00 $3,000.00 $3,000.00 $3,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.19B $964.67M $958.43M $958.43M $903.58M
Retained Earnings -$800.35M -$753.71M -$711.30M -$711.30M -$683.45M
Gains/Losses Not Affecting Retained Earnings $769,000.00 $985,000.00 -$192,000.00 -$192,000.00 -$1.14M
Current Deferred Liabilities – – $0.00 $0.00 $5.49M

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$40.43M -$40.88M -$93.09M -$26.72M -$24.17M
Net cash flow from continuing operations -$40.43M -$40.88M -$93.09M -$26.72M -$24.17M
Net Income from Continuing Operations -$46.64M -$42.41M -$109.00M -$27.85M -$32.73M
Depreciation & Depletion & Amortization $291,000.00 $295,000.00 $1.15M $299,000.00 $286,000.00
Other Non-Cash Items -$4.66M $344,000.00 $5.63M $3.64M $673,000.00
Change in Working Capital $4.77M -$4.65M -$5.37M -$7.07M $4.03M
-Change in Prepaid Assets -$645,000.00 -$794,000.00 -$1.73M -$2.14M $971,000.00
-Change in Payables and Accrued Expense $5.42M -$3.86M $6.14M $548,000.00 $3.06M
Net cash flow from investing $1,000.00 -$3.02M -$604,000.00 -$247,000.00 -$48,000.00
Net Cash Flow from Continuing Investing Activities $1,000.00 -$3.02M -$604,000.00 -$247,000.00 -$48,000.00
Net PPE Purchase and Sale $1,000.00 -$24,000.00 -$738,000.00 -$250,000.00 -$108,000.00
Net Intangibles Purchase and Sale $0.00 -$3.00M – – –
Financing Cash Flow $216.66M $711,000.00 $274.59M $49.56M $8.80M
Net Cash Flow from Continuing Financing Activities $216.66M $711,000.00 $274.59M $49.56M $8.80M
Proceeds from Stock Option Exercised $441,000.00 $692,000.00 $1.38M $1.02M $281,000.00
Net Other Financing Charges $75,000.00 $19,000.00 -$337,000.00 -$57,000.00 -$271,000.00
Ending Cash Balance $455.57M $279.34M $322.53M $322.53M $299.94M
Net Change in Cash $176.23M -$43.19M $180.90M $22.59M -$15.42M
Beginning Cash Balance $279.34M $322.53M $141.64M $299.94M $315.36M
Free Cash Flow -$40.42M -$43.90M -$93.83M -$26.97M -$24.27M
Gain/Loss from Continuing Operations – – $1.20M $736,000.00 $292,000.00
-Change In Other Working Capital – – -$9.77M -$5.49M $0.00
Net Other Investing Changes – – $134,000.00 $3,000.00 $60,000.00
Net Issuance Payments Of Debt – – $9.24M $0.00 –
Net Common Stock Issuance – – $264.31M $48.59M -$454,000.00

Discussion

No comments yet — be the first to weigh in on TSHA.

Sign in to join the discussion.

Scroll to Top